B cell and B cell-related pathways for novel cancer treatments.

Tokunaga, Ryuma; Naseem, Madiha; Lo, Jae Ho; Battaglin, Francesca; Soni, Shivani; Puccini, Alberto; Berger, Martin Dave; Zhang, Wu; Baba, Hideo; Lenz, Heinz-Josef (2019). B cell and B cell-related pathways for novel cancer treatments. Cancer treatment reviews, 73, pp. 10-19. Elsevier 10.1016/j.ctrv.2018.12.001

[img] Text
1-s2.0-S0305737218301993-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (981kB) | Request a copy

B cells are recognized as the main effector cells of humoral immunity which suppress tumor progression by secreting immunoglobulins, promoting T cell response, and killing cancer cells directly. Given these properties, their anti-tumor immune response in the tumor micro-environment (TME) is of great interest. Although T cell-related immune responses have become a therapeutic target with the introduction of immune checkpoint inhibitors, not all patients benefit from these treatments. B cell and B cell-related pathways (CCL19, -21/CCR7 axis and CXCL13/CXCR5 axis) play key roles in activating immune response through humoral immunity and local immune activation via tertiary lymphoid structure (TLS) formation. However they have some protumorigenic works in the TME. Thus, a better understanding of B cell and B cell-related pathways is necessary to develop effective cancer control. In this review, we summarize recent evidences regarding the roles of B cell and B cell-related pathways in the TME and immune response and discuss their potential roles for novel cancer treatment strategies.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Berger, Martin Dave

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1532-1967

Publisher:

Elsevier

Language:

English

Submitter:

Rebeka Gerber

Date Deposited:

08 Mar 2019 14:27

Last Modified:

03 Nov 2019 09:28

Publisher DOI:

10.1016/j.ctrv.2018.12.001

PubMed ID:

30551036

Uncontrolled Keywords:

B cells CCL19, −21/CCR7 axis CXCL13/CXCR5 axis Cancer TLS Tfh cells

BORIS DOI:

10.7892/boris.124076

URI:

https://boris.unibe.ch/id/eprint/124076

Actions (login required)

Edit item Edit item
Provide Feedback